title: Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
abstract: The aim of this study was to evaluate the quality of life and the intensity of the injection site reactions during the first 6 months of treatment with enfuvirtide according to the counseling and training provided by nurses and physicians. In this prospective, 6-month cohort, 61 HIV-1 infected adult patients starting enfuvirtide have been included. At baseline, 82% of the patients have either read information documents (23%) or received counseling (59%); 18% were self-injectors, 27.8% had a dual disposition (self-injector + third person), and 49.2% were injected by a third person. At month 6, among the 43 patients still on enfuvirtide, 59% have had no change in injection disposition, and 52% have the dual disposition. Quality of life and enfuvirtide acceptance improved during 6 months. With adequate education and choice of injection dispositions, treatment with enfuvirtide can lead to quality-of-life improvements.
authors.affiliation: Department of Infectiology, Hôtel Dieu, Nantes. clotilde.allavena@chu-nantes.fr
authors.forename: Clotilde
authors.initials: C
authors.lastname: Allavena
authors.forename: Thierry
authors.initials: T
authors.lastname: Prazuck
authors.forename: Véroniquer
authors.initials: V
authors.lastname: Reliquet
authors.forename: Renaud
authors.initials: R
authors.lastname: Verdon
authors.forename: Philippe
authors.initials: P
authors.lastname: Perré
authors.forename: Gwenael
authors.initials: G
authors.lastname: Le Moal
authors.forename: Eric
authors.initials: E
authors.lastname: Billaud
authors.forename: François
authors.initials: F
authors.lastname: Raffi
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003376:Counseling; D004359:Drug Therapy, Combination; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage / Q000009:adverse effects; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D018894:Reverse Transcriptase Inhibitors; D000077560:Enfuvirtide